EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Immune checkpoint inhibitor‐induced myasthenia gravis, myocarditis, and myositis: A case report

Arjun Basnet, Nava Raj Sharma iD, Sudarshan Gautam, Saral Lamichhane iD, Sajog Kansakar, Kripa Tiwari, Madalasa Pokhrel, Sehajpreet Singh

Clinical Case Reports · 2024-06 · 12 (6)

DOI: 10.1002/ccr3.8968 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 10.06.2024. Verfasst von Arjun Basnet und 7 weiteren Autor:innen. Beteiligte Einrichtung: Maimonides Medical Center Brooklyn New York USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Clinical Message Immune checkpoint inhibitors can rarely lead to occurrence of myositis, myocarditis, and myasthenia gravis (MG). Early recognition and multidisciplinary management are crucial for optimal outcomes. Vigilance for overlapping toxicities is essential in patients receiving combination immunotherapy. Abstract The use of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, but it is associated with immune‐related adverse events (IRAEs) affecting various organ systems. The simultaneous occurrence of MG, myocarditis, and myositis highlights the complex nature of IRAEs. Early recognition and comprehensive multidisciplinary management are crucial for optimal patient outcomes. We present a unique case report of a 76‐year‐old male patient with advanced melanoma who developed concurrent myositis, myocarditis, and MG while receiving combination immunotherapy with Nivolumab and Ipilimumab. This case underscores the significance of recognizing and addressing the “Terrible Triad” of IRAEs in patients receiving ICIs. Healthcare providers should maintain a high index of suspicion for overlapping toxicities and promptly initiate appropriate interventions.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorsmyastheniamyocarditismyositis

Autor:innen und Institutionen

  • Maimonides Medical Center Brooklyn New York USA.
  • Manipal College of Medical Sciences Pokhara Nepal.
  • Gandaki Medical College Pokhara Nepal.
  • Montefiore New Rochelle Hospital New Rochelle New York USA.

ORCID-Profile: Nava Raj Sharma, Saral Lamichhane

Zitieren

APA

Basnet, A., Sharma, N. R., Gautam, S., Lamichhane, S., Kansakar, S., Tiwari, K., Pokhrel, M., & Singh, S. (2024). Immune checkpoint inhibitor‐induced myasthenia gravis, myocarditis, and myositis: A case report. Clinical Case Reports, 12(6). https://doi.org/10.1002/ccr3.8968

Vancouver

Basnet A, Sharma NR, Gautam S, Lamichhane S, Kansakar S, Tiwari K, et al. Immune checkpoint inhibitor‐induced myasthenia gravis, myocarditis, and myositis: A case report. Clinical Case Reports. 2024;12(6). doi:10.1002/ccr3.8968

BibTeX
@article{Basnet2024,
  author = {Basnet, Arjun and Sharma, Nava Raj and Gautam, Sudarshan and Lamichhane, Saral and Kansakar, Sajog and Tiwari, Kripa and Pokhrel, Madalasa and Singh, Sehajpreet},
  title = {Immune checkpoint inhibitor‐induced myasthenia gravis, myocarditis, and myositis: A case report},
  journal = {Clinical Case Reports},
  year = {2024},
  volume = {12},
  number = {6},
  doi = {10.1002/ccr3.8968}
}
Kostenlos starten →